Rational cyclodextrin formulation design through insights into drug release mechanism in the gastrointestinal tract via molecular dynamics simulations.

J Pharm Sci

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China; Faculty of Health Sciences, University of Macau, Macau, 999078, China. Electronic address:

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cyclodextrin formulations are crucial for enhancing the solubility of drugs. Bile salts are recognized as potential agents for displacing drugs from cyclodextrin formulations in intestinal fluids. However, the mechanism underlying this displacement remains unclear. This study aims to investigate the mechanism of competitive displacement using molecular dynamics simulations and to develop guidelines for effective cyclodextrin formulation design. The umbrella sampling method is employed to investigate the binding free energy between bile salts and cyclodextrin molecules, while metadynamics is utilized to simulate the dynamic replacement process. The results indicate that the optimal binding free energy interval between cyclodextrins and drugs ranges from -30 kJ/mol to -8 kJ/mol. Additionally, the optimal concentration ratio between drugs and cyclodextrins can be calculated based on the binding free energy. Displacement simulations showed that free single bile salt molecules are more likely to complete the displacement compared to clusters of bile salts. This suggests that the bioavailability of cyclodextrins may be higher in fasting conditions than in the fed state. This study will not only enhance our understanding of the relationships between cyclodextrin formulations and bile salts but also facilitate the rational design of more effective pharmaceutical formulations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2025.103760DOI Listing

Publication Analysis

Top Keywords

bile salts
16
cyclodextrin formulations
12
binding free
12
free energy
12
cyclodextrin formulation
8
formulation design
8
molecular dynamics
8
dynamics simulations
8
cyclodextrin
5
bile
5

Similar Publications

Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC.

View Article and Find Full Text PDF

Unlabelled: Lactose intolerance is defined as the inability to digest lactose due to insufficient activity of the β-galactosidase enzyme, which catalyzes the hydrolysis of lactose into glucose and galactose. This study evaluated the potential probiotic properties of isolated S8, which exhibiting high β-galactosidase activity. The strain demonstrated higher survival rate under gastrointestinal stress, with 80% and 63% viability after 3 h in simulated gastric fluid and 8 h in intestinal fluid, respectively, while retaining 60.

View Article and Find Full Text PDF

Limosilactobacillus fermentum CRL2085, isolated from feedlot cattle rations, displayed high efficiency as a probiotic when administered to animals. A comprehensive genomic analysis was performed to elucidate the genetic basis underlying its probiotic potential. Fifteen genomic islands and CRISPR-Cas elements were identified in its genome.

View Article and Find Full Text PDF

Pyroptosis is a lytic and pro-inflammatory regulated cell death pathway mediated by pores formed by the oligomerization of gasdermin proteins on cellular membranes. Different pro-inflammatory molecules such as interleukin-18 are released from these pores, promoting inflammation. Pyroptotic cell death has been implicated in many pathological conditions, including cancer and liver diseases.

View Article and Find Full Text PDF

The farnesoid X receptor (FXR), expressed in the liver and in the small intestine, is a key regulator of glucose and lipid metabolism. Its pharmacological modulation is explored as a potential treatment for obesity-related metabolic impairments. To develop effective pharmacological interventions, it is crucial to differentiate the individual contributions of intestinal and hepatic FXR to lipid metabolism.

View Article and Find Full Text PDF